Shanghai Hengrui Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-12-04
- Employees
- -
- Market Cap
- -
- Website
- http://www.shhrp.com
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Adebelimab InjectionDrug: Ametinib Mesylate Tablets
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06895928
- Locations
- 🇨🇳
Shanxi Cancer hospital, Taiyuan, Shanxi, China
A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Phase 1
Active, not recruiting
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: [14C] SHR6508 Injection
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT06877247
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, Shandong, China
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Phase 3
Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06738251
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06704828
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Phase 2
Recruiting
- Conditions
- Advanced Gynecological Malignancy
- Interventions
- Drug: SHR-A2102 for injection
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06654440
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Paclitaxel, Docetaxel, Irinotecan
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 524
- Registration Number
- NCT06649292
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06639347
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SHR-7787 injection
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT06605222
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT06589778
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Drug: SHR-A2102ï¼›Adebrelimabï¼›Cisplatin/ Carboplatin
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT06512051
- Locations
- 🇨🇳
Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath